News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter

Ark Therapeutics Release: Appointment of CFO, Russell Banks

3/3/2011 11:22:38 AM

London, UK, 3 March 2011 – Ark Therapeutics Group plc (the “Company” or “Ark”) announces that Russell Banks has accepted the position of Chief Financial Officer with effect from 1 March. Russell was European Finance Director for Cephalon, Inc. for over ten years, where he held financial responsibility for its European business and played a key role in developing the European operations of a rapidly growing organisation.

Mr. Banks succeeds David Bowyer who has stepped down from the role following his decision to return to his native Zimbabwe to take on a senior financial and operational role in a major Zimbabwean company.

Martyn Williams, CEO of Ark said: “I am delighted that Russell has joined Ark bringing as he does a wealth of experience in developing healthcare businesses both organically and through acquisition and I have every confidence he will play a full part in helping us to meet our strategic objectives. I would like to extend my thanks to David who joined Ark in 2004 and who has made a considerable contribution to the Company over nearly seven years.”


For further information please contact:

Ark Therapeutics Group plc Tel: + 44 (0)20 7388 7722 Martyn Williams, CEO Iain Ross, Chairman

Financial Dynamics Tel: +44 (0)20 7831 3113 Ben Atwell Susan Quigley

Ark Therapeutics Group plc

Ark Therapeutics Group plc is a specialist healthcare group (the "Group") addressing high value areas of unmet medical need within vascular disease and cancer. These are large and growing markets, where opportunities exist for effective new products to generate significant revenues.

Ark has an early stage pipeline emanating from collaborations with University College, London and the AI Virtanen Institute in Kuopio, Finland, the development of which it intends to progress in collaboration with pharmaceutical and biotech partners.

In addition Ark has the ability to off-set a proportion of its R&D costs and to generate sustainable revenues through the exploitation of its proprietary technology platform, process development, scale-up and manufacturing capabilities on behalf of third parties.

Ark has its origins in businesses established in the mid-1990s by Professor John Martin and Mr Stephen Barker of University College London and Professor Seppo Ylä-Herttuala of the AI Virtanen Institute at the University of Kuopio, Finland, all of whom remain consultants on the Company's research and development programmes.

Ark's shares were first listed on the London Stock Exchange in March 2004 (AKT.L).

This announcement includes "forward-looking statements" which include all statements other than statements of historical facts, including, without limitation, those regarding the Group's financial position, business strategy, plans and objectives of management for future operations (including development plans and objectives relating to the Group's products and services), and any statements preceded by, followed by or that include forward-looking terminology such as the words "targets", "believes", "estimates", "expects", "aims", "intends", "will", "can", "may", "anticipates", "would", "should", "could" or similar expressions or the negative thereof. Such forward-looking statements involve known and unknown risks, uncertainties and other important factors beyond the Group's control that could cause the actual results, performance or achievements of the Group to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. Such forward-looking statements are based on numerous assumptions regarding the Group's present and future business strategies and the environment in which the Group will operate in the future. Among the important factors that could cause the Group's actual results, performance or achievements to differ materially from those in forward-looking statements include those relating to Ark's funding requirements, regulatory approvals, clinical trials, reliance on third parties, intellectual property, key personnel and other factors. These forward-looking statements speak only as at the date of this announcement. The Group expressly disclaims any obligation or undertaking to disseminate any updates or revisions to any forward-looking statements contained in this announcement to reflect any change in the Group's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based. As a result of these factors, readers are cautioned not to rely on any forward-looking statement.

Juliet Edwards Assistant Financial Dynamics Holborn Gate, 26 Southampton Buildings London, WC2A 1PB D +44 (0)20 7269 7125

Read at

comments powered by Disqus